<h4>Background</h4>Chimeric antigen receptor-modified T cells (CAR-T) targeting CD19 has produced a high durable response in refractory or relapsed diffuse large B-cell lymphoma. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.